GLTO Galecto

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating at the upcoming H.C. Wainwright’s 24th Annual Global Investment Conference taking place on September 12-14, 2022. Details for the event are as follows:

H.C. Wainwright 24th Annual Global Investment Conference
Date: September 12-14, 2022
Webcast: 

Management will be available for virtual 1x1 meetings with investors. Please contact your H.C. Wainwright representative to request a meeting.

A replay of the webcast presentation will be available in the Investor section of Galecto’s website at .

About Galecto

Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit .

For more information, contact:

Galecto, Inc. 
Hans Schambye, CEO

 
Jon Freve, CFO 
 
  
Investors/USMedia/EU
Ashley R. Robinson

Sandya von der Weid
+1 617 430 7577


EN
06/09/2022

Underlying

GLTOGalecto

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galecto

 PRESS RELEASE
Free
GLTO GALECTO

Galecto Reports First Quarter 2025 Operating and Financial Results

Galecto Reports First Quarter 2025 Operating and Financial Results BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025. “During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML,” said Dr. Hans Schambye, CEO of Galecto. “We continued preclinical studies to support our planned IND submission, wh...

May 8, 2025 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Reports Full-Year 2024 Financial Results

Galecto Reports Full-Year 2024 Financial Results Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge MedicinesGB3226 on track for IND submission in Q1 2026Phase 2 investigator-initiated trial (IIT) of GB1211 in combination with pembrolizumab (Keytruda®) in metastatic melanoma and head and neck squamous cell carcinoma continues to enroll patients BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a c...

March 19, 2025 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto to Participate in Upcoming Investor Conferences

Galecto to Participate in Upcoming Investor Conferences BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One MeetingsDate and Time: Wednesday, February 12 at 8:40-9:10 AM   Location: Virtual A live webcast of the presentation will ...

February 6, 2025 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Reports Third Quarter 2024 Financial Results

Galecto Reports Third Quarter 2024 Financial Results -  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines -  Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for...

November 1, 2024 1 EN
 PRESS RELEASE
Free
GLTO GALECTO

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wec...

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. “We are thrilled to welcome Dr. Wechsler to our Board of Directors,” said Dr. Carl Goldfischer, Chair of the Board of Galecto. “Amy is...

October 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch